Qrono
Qrono Inc. is a biotechnology company focused on developing innovative therapies to harness the immune system against cancer. Their platform, Eloquent™, uses optimized polymer particles to unmask cancer threats and stimulate robust immune responses. They aim to improve cancer treatment by activating antigen presenting cells to better communicate with T cells, thereby enhancing the body's ability to fight tumors.
Industries
biotechnology
health-care
pharmaceutical
Nr. of Employees
small (1-50)
Qrono
2403 Sidney Street, Suite 255, Pittsburgh, PA 15203
Products
Polymer particle–based controlled‑release immunotherapy platform
A therapeutic platform employing mathematically optimized polymer particles to deliver agents to antigen presenting cells, selectively modulate APC feedback, and promote tumor‑specific T cell responses.
Polymer particle–based controlled‑release immunotherapy platform
A therapeutic platform employing mathematically optimized polymer particles to deliver agents to antigen presenting cells, selectively modulate APC feedback, and promote tumor‑specific T cell responses.
Expertise Areas
- Controlled-release drug delivery
- APC-targeted immunotherapy
- Neoantigen-focused therapeutic design
- Polymer particle formulation
Key Technologies
- Polymer particle drug delivery
- Antigen-presenting cell targeting
- Neoantigen-directed immunotherapy
- Computational optimization of release kinetics